The increased price target reflects the firm's recognition of BankUnited (NYSE:BKU)'s consistent progress and its potential ...

RBC Capital Markets adjusted its outlook on Ally Financial Inc. (NYSE: NYSE:ALLY), raising the firm's price target on the stock to $45.00, up from the previous figure of $41.00. The investment firm ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

RBC says it already uses AI in customer service, staff guidance, and to help the productivity of research analysts in its capital markets business, while TD says it uses AI to help its call centre ...

Fintel reports that on January 7, 2025, RBC Capital upgraded their outlook for Carvana (LSE:0A79) from Sector Perform to Outperform. There are 997 funds or institutions reporting positions in Carvana.

Acknowledging that there is skepticism surrounding its business model and ability to sustain profitability targets, RBC Capital joins the growing list of bulls in support of Carvana, raising its ...

Fintel reports that on January 6, 2025, RBC Capital downgraded their outlook for T-Mobile US (BRSE:TMUS) from Outperform to Sector Perform. There are 2,603 funds or institutions reporting ...

Investing.com -- RBC Capital Markets on Monday upgraded Carvana (NYSE:CVNA) shares to Outperform, and lifted the target price to $280 from $270. According to the firm’s analysts, following ...

RBC Capital Markets analysts have downgraded T-Mobile to Sector Perform from Outperform and reduced their price target to $240 per share from $255.While acknowledging the company's strong ...

On Thursday, RBC Capital Markets adjusted their stance on Neumora Therapeutics (NASDAQ:NMRA), downgrading the stock from an Outperform to a Sector Perform rating. This change comes in the wake of ...